• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    This invention relates to enzyme inhibitory, novel phthalazin-4-ylacetic acid derivatives of the general formula wherein R1 is a hydroxy or benzyloxy radical, or a C1-4- alkoxy radical optionally bearing an N-morpholino or a C1-4-alkylamino radical, X is oxygen or sulfur, the rings A and B may be substituted, pharmaceutically acceptable salts as appropriate, to pharmaceutical compositions thereof, and to analogy processes for their manufacture. The compounds of formula I are inhibitors of the enzyme aldose reductase in vivo and as such may be useful in the reduction or prevention of the development of the peripheral effects such as macular oedema, cataract, retinopathy or impaired neural conduction. A preferred compound is 2-(2-fluoro-4-bromobenzyl)-1,2-dihydro-1-oxophthalazin-4- ylacetic acid.
    公开号:SU1272984A3
    申请号:SU813359216
    申请日:1981-12-04
    公开日:1986-11-23
    发明作者:Роберт Бриттэйн Дэвид；Вуд Робин
    申请人:Империал Кемикал Индастриз Лимитед (Фирма)；
    IPC主号:
    专利说明:

    where the halogen, X, and the substituents in the benzene rings A and B have the indicated values, undergo hydrolysis, and the desired product is isolated in free form or as a salt. 2. A method according to claim I, about tl and h and y and the fact that the process 1 4 in the presence of aqueous conduct acid at 45 mineral. 3. The method according to claim 1, characterized by the fact that the process is carried out in the presence of an alkaline hydroxide or carbonate at 18P ° C.
    This invention relates to a process for the preparation of phthalazin-4-yl-acetic acid derivatives, which contribute to the inhibition of enzymatic aldose reductase in a living organism, and can be used in medicine. The purpose of the invention is a method for producing novel phthalazin-4-yl-acetic acid derivatives, which contribute to the inhibition of enzymatic aldose reductase in a living organism. Example 1. A mixture of ethyl-1,2-dihydro-1-o KS of alazin-4-yl-acet at a (11.5 g) and sodium hydride (2.7 g, dispersion with a 50% weight ratio in oil) in dimethylformamide (125 ml) is stirred at .1 h in a nitrogenous medium. The resulting solution is cooled to room temperature, then 4-bromo-3-chlorobenzyl bromide (15.0 g) is added to the solution, after which the mixture is stirred for 2 hours. After cooling to reaction mixture, I add T to water (500 ml). The resulting aqueous mixture was extracted with ethyl acetate (400 ml). The extracts were washed with water, dried with MgSO4 and implanted, resulting in a solid, which was crystallized from propan-2-ol to give ethyl-2- (3-clop-4-brombenzyl) -, 2-dihydro-1-a1 Xoftalazin-4 -yl acetate (7.3 g), so pl. 142-145 ° C. Examples 2 and 3, The process is carried out analogously to example 1. Compounds having the formula CH CO-iEi are obtained in which the ring in is unsubstituted, from ethyl-1,2-dihydro-2-oxoalazin-4-yl-acetate and the corresponding bromide, having the formula abl. one). Br - CH2 / A (V) Table 1 3,4-Di- 40 i-PrOH chlorine 2-Fluoro-4-bromo 3,4-dichlorobene chloride is used as the starting material. Example 4, Ethyl-2- solution. 3-chloro-4-brombeizl) -1,2-dihydro-oxoftalazin-4-yl-acetate (7.0 g) ethanol (70 ml), containing hydrochloride drip (7.0 g), heated with about 3,172 refrigerators for about 30 min. After this, the solution is poured into water (250 ml) and the aqueous solution is extracted with ether (2 x 150 ml). The aqueous phase is acidified to a pH of 2; concentrated; hydrochloric acid bath. The solid that has precipitated is separated, washed with water, dried under vacuum, and then recrystallized from a mixture of 10 Toluene, propan-2-ol and petrol (6080) in a volume ratio of 6: 2: 3, resulting in 2- (3-chloro-4-6poM6eH3Hji) -1,2-DIGIDRO-1-OXO-phthalazin-4-yl-acetic acid (5 (3.9 g), so pl. 186C.
    2-Fluoro-4-bromo Example 2- (3,4-d1-chlorobenzyl) -7-methoxy-1,2-dihydro-1-oxophthalazin-4-yl-acetic acid (1.9 g) in Onyl chloride ( 10 ml) containing dimethylformamide (0.1 ml) is heated under reflux for 3 hours. After that, the resulting solution is evaporated. The residue is dissolved in dry toluene and the solution is evaporated. This procedure is carried out three times, allowing to obtain 2- (3,4-dichloro-benzyl) -7-methoxy-1,2-di acid chloride; hydro-1-oxophthalazine-4-ip-carboxylic acid in the form of a solid substance having satisfactory infrared spectrum. A solution of the indicated acid chloride in dry tetrahydrofuran (50 ml) is added dropwise to a stirred solution of diazomethane in dry ether (200 ml), cooled to N-methyl-N-nitrosome distillate (10 g
    184-185
    Methanol: The compound may crystallize in polymorphic forms, i.e. acquiring the form 184-185С (from methanol containing some amount of water) and form 180-182 ° C (as a result of two crystallizations from dry methanol). . Stirred mixture After the end of the addition, add another 4 Examples 5 and 6. Process; carried out analogously to example 4. Compounds having the formula CHaCO H are obtained in which the ring in is unsubstituted. The compounds are obtained by hydrolysis of the corresponding ethyl ether having the formula (I) (Table 2). Table2 was stirred and allowed to warm to room temperature over 2 hours. Thereafter, the mixture was separated by filtration. The resulting residue is washed with dry tetrahydrofuran (20 ml), after which the combined water and the filtrate are evaporated to give 2- (3,4-dichlorobenzyl) -4- (c (-diazo) acetyl-7-methoxy-1, 2- dihydro-1-oxophthalazine as a solid, which is used without purification or identification. A solution of silver benzoate (0.2 g) in triethylamine (1 ml) is slowly added dropwise to a solution of the said 4- (a-diazo) derivative α-acetyl in absolute ethanol (50 ml) and tetrahydrofuran (30 ml) heated under reflux (After such addition the gas is violently separated, the solution is then added only after the end of this process.) After the addition is complete, the reaction mixture is stirred and refluxed for 30 minutes, then the mixture is filtered hot. The filtrate is evaporated and the resulting residue is dissolved in ethyl acetate (200 ml). A solution of ethyl: acetate is washed with water (3x100 ml), dried with MgSO4 and evaporated. This residue is purified by chromatography on silica gel (100 g) using an increasing concentration of ethyl acetate in toluene as a quality eluent. As a result of this, TLC on silica gel plates using ethyl acetate: toluene ratio of 1: 3 (as eluent) ethyl-2- (3,4-dichlorben .zil) -7- was obtained from the corresponding fractions (judging by the resolution of thin layer chromatography) by TLC on silica gel plates. methoxy-1,2-dihydro-1-oxoftalazin-4-yl-acetate (0.9 g), so pl. 129-130 ° C. The original substance is obtained as follows. a) A mixture of 7-methoxy-1,2-dihydro-1, -oxoftalazin-4-yl-carboxylic acids (10.0 g), sodium bicarbonate (15.0 g and methyl iodide (15.0 g) in dry dimethylformamide (200 ml) is stirred at room temperature for 16 hours. This mixture is then poured into water (600 ml). The precipitated solid is separated, washed with water and then with cold methanol, after which it is recrystallized from methanol to form methyl 7-methoxy-1,2-dihydro-1-oxoftapazin-4-yl-carboxylate (8.6 g), mp 222-225 C. S) A solution of methyl ester (8.29 g) prepared according to .about , dry dimethylformamide (200 ml) rabatshayut of sodium hydride (1.75 g dispersion in oil with weight ratio sy, ravnpm 50%). This mixture is stirred and cooled to room temperature for one hour, after which 3,4-dichlorobenzene chloride (7.0 g) is added to it. The mixture was stirred at room temperature for 2 hours, after which it was poured into water (600 ml). The solid formed is separated, washed with water, dried in Kuum, and then recrystallized from a mixture of propan-2-ol and petrol (60-80) with a volume ratio of 3: 3 to form methyl 2- (3,4-dichlorobeneyl) -7-methoxy-1,2-dihydro-1-oxofapazin-4-yl-carboxylate (9.0 g), so pl. 144-146 ° C. B) A solution of methyl ester (9.0 g) obtained in S, in ethanol (100 ml) and water (100 ml) containing potassium hydroxide (10.0 g), is heated under reflux for 4 hours The resulting solution is diluted with water (200 ml) and acidified to pH 2 with concentrated hydrochloric acid. The solid precipitated as a result of this was separated, washed with water, dried in a vacuum, and recrystallized from a mixture of propan-2-ol and dimethylformamide with a volume ratio of 1: 1 to form 2- (3,4-dichlorobenzyl) -7-methoxy-1, 2-dihydro-1-oxoftalazin-4-yl-carboxylic acid (6.1 g), i.e. 238240 ° C. 7-Methoxy-1,2-dihydro-1-oxophthalazin-4-yl-carboxylic acid is obtained in the form of a solid, tons. 229-230 ° C, in accordance with the method developed by Vagan et al. Example 8. The process is carried out analogously to example 7, but starting with 2- (3,4-dichlorobeneyl) -7-chloro-1,2-dihydro- 1 -oxoftapazin-4-yl-carboxylic acid (A). An 8% yield of ethyl 2- (3,4-dichlorobenzyl) -7-chloro-1, 2-dihydro-1-oxophthalazine-4yl acetate is obtained in the form of a solid, and has a satisfactory nuclear magnetic resonance spectrum. The starting carboxylic acid derivative (A) is prepared according to PP-6, but the procedure starts with 7-chloro-1,2-dihydro-I-oxophthalazin-4-yl-carboxylic acid (B). Intermediate substances are characterized by the following melting points: according to para, a: methyl 7-chloro-1,2-dihydro-1-oxophthal azin-4-yl-carboxylate, m.p. 255-257 ° C (recrystallized from a mixture of methanol and dimethylformamide with a volume ratio of 2: 1); as claimed in S: methyl 2- (3,4-dichlorobenzyl) -7-chloro-1,2-dihydro-1-oxophthalazin-4-yl-carboxylate, m.p. 178-180 ° C (recrystallized from a mixture of propan-2-ol and petrol (60-80) with a volume ratio of 1: 3); by P. & : 2- (3,4-dichlorbeisyl) 7-1, 2-dngidro-1-ocEophthalazin-4-yl-carbaic acid, so pl. 260-262С (recrystalline crystallization from a mixture of methanol and dimethylformamide with a volume ratio of 1: 1). The carboxylic acid (B) is obtained as a solid,. 241243 C; in accordance with the method developed by Vagan et al., but the procedure starts with 4-chloro-2-methylethathenone. Examples 9 and 10. The process is carried out analogously to Example 4, but it begins with the corresponding ethyl ester. In example 9, get 2- (3,4-dichlorobenzsh1) -7-methoxy-1,2-dihydro-1-oxoftalazin-4-yl-acetic acid, so pl. 193-200 ° C (recrystallized from lost-2-ol), yield 50%. In example 10, receive 2- (3,4-dichlorobenzyl) -7-xpor-1,2-dihydro-1-oxophthalazin-4-yl-acetic acid, so pl. 203-205 ° C (recrystallized from a mixture of propan-2-ol and petrol (60-80) with a volume ratio of 1: 1), yield 43%. Examples 11 and 12. The process is carried out analogously to example 1. As a result of the use of benzyl bromide or chloride, the following esters are obtained. In Example 11, ethyl-2- (2-fluoro-4-chlorobenzyl) -1,2-dihydro-1-ca softapazin-4-yl-ace, tat is obtained, m.p. 102 C (recrystallized from petrol (60-80), and then from ethanol), yield 45%. In Example 12, ethyl 2- (2-fluoro-4-iodobenzyl) -1,2-dihydro-1-oxophthalazin-4-yl-acetate is obtained, m.p. 113 ° C (recrystallized from petrol (60-80), yield 50%. Examples 13-15. The process is carried out analogously to example 4, but it is started with the corresponding ethyl ester. In example 13, 2- (2-fluoro- 4-chlorobenzyl) -1,2-dihydro-1-oxoftalazin-4-yl-acetic acid, mp 193-194 ° C (recrystallized from a mixture of ethanol and water in a volume ratio of 3: 1), yield 63%. Example 14, 2- (2-fluoro-4-iodobenzyl) -I, 2-dihydro-1-oxophthalazin-4-yl-acetic acid, m.p. 189C (recrystallized from a mixture of ethanol and water with a volume ratio of 3: 1 55%. For example, 15 2- (3-chloro-4-bromobenzyl) -1,2-dihydro-1-thioxophthalazin-4-yl-acetic acid is obtained, mp 197-199 ° C (recrystallized from propan-2-ol), yield 25%. The hydrolysis is carried out with an aqueous solution of sodium hydroxide in methanol for 10 minutes under reflux. Example 16. A mixture of ethyl 2- (3-chloro-4-bromobenzyl) -1,2-dihydro-1- oxoftalazin-4-yl-acetate (1.8 g) and five times more phosphorus (2.5 g) in xylene (.100 ml) are stirred and refluxed for 1 hour. The reaction solution is then cooled to room temperature, it is added ethyl acetate (25 ml), after which the mixture is filtered through chromatographic silica gel (20 g), the resulting filtrate is evaporated, and the resulting solid is recrystallized from ethanol to form ethyl 2- (3-chloro-4-bromobenzyl) -1,2-dihydro -1-thioxoftapazin-4-yl acetate (1.1 g), m.p. 124126 ° C. Examples 17-22. The process is carried out in a manner similar to Example I, but with the addition of the corresponding methyl benzyl having the formula (V). Compounds of formula (IV) are obtained, of which ring B is unspecified (Table 3). Table 3 Examples 23-25. Ethyl 4-methyl 3-oxo-d1a-phthalane acetate (2.29 g) is heated and stirred under reflux in toluene (200 ml.) While adding 3,4-dichlorobenzylhydrazine (1.9 ml) to the process of adding dropwise. in toluene (50 ml). The mixture is heated under reflux for 3 hours, cooled and evaporated. The residue from the solid is recrystallized from CMecji isopropanol and petrol (60-80) in a volume ratio of 1: 2 to form ethyl -2- ( 3, 4; -dichlorobenzyl) -8-metsh1-1,2-di hydro-1-oxofapazin-4-yl-acetate (example 23) (1.4 g), mp 1341370. An. Similarly, but starting from ethyl 4-fluoro-3-oxophthalate acetate, ethyl 2- (3,4-dichlorobenzyl) -8-fluoro-1, 2-dihydro-1-oxoftapazin-4-Sh1-acetate is obtained (Example 24), t. mp 177178 ° C (recrystallized from a mixture of isopropanol and petrol (60--80) with a volume ratio of 1: 2), yield 37%. Similarly, start with a mixture of 1: 1 5-methyl- and 6 mets-1-3 -oxo-ula-phthalate, get a mixture of 1: 1 ethyl-6-methyl- and 7-methyl-2- (3,4 dichlorobenzyl) -1,2-dihydro-1-oxoft alazin-4-1sh acetate (example 25 ), mp 120-122 ° C (perecrystallized from isopropanol), 33% yield. The starting materials are prepared as follows. A solution of 3-fluorophthalic anhydride (7.35 g) and (carbethoxymethylene) -triphenylphosphorane (17.5 g) in dry 1,2 dimethoxyethane (200 ml) is stirred and heated under reflux in nitrogen atmosphere for 16 h. The solvent is then evaporated and the residue adsorbed onto chromatographic silica gel (11b (20 g). This silica gel is then added to the top of the column of the same silica gel (300 g), after which the column is eluted with toluene. The eluate is analyzed by thin-layer chromatography (silica gel: eluate from toluene / ethyl acetate) about 9: 1), after which the first fractions containing the substance visible in the ultraviolet spectrum are combined and evaporated.The resulting solid is recrystallized from isopropanol to form ethyl 4-fluoro-3-oxo-CilQ-phthalanacetate (2, 3 g), mp: 101-103 ° C. In a similar manner, ethyl-4-methyl-3-oxo-ulQ-phtapanacetate (Example 23) is obtained as a solid, mp 84-86 ° C, yield 56% after recrystallization from isopropanol, and the procedure starts with 3-methylphthalic anhydride. In a similar manner, a mixture of 1: 1 ethyl 5-methyl- and 6-methyl-3-oxo-l1a-phthalanacetate (Example 25) is obtained as a solid, 40% m.p. 84-86 C (recrystallized from isopropanol), and the procedure starts with 4-methylesphthalic anhydride. Examples 26-28. The process is carried out analogously to example 1 from the corresponding substituted 1,2-dihydro-1.-Oxophthalazin-4-yl-acetate and 2-fluoro-4-bromobenzenshgidrazin. In example 26 get ethyl-2-. - (2-fluoro-4-brombeizish1) -8-fluoro-1,2-dihydro-1-oxo-phthalazin-4-yl-acetate, so pl. 128-130 ° C (recrystallized from a mixture of isopropanol and petrol (60-80) with a volume ratio of 1: 3) yield 36%. In Example 27, ethyl-2- (2-fluoro-4-bromobenzyl) -8-methyl-1,2-dihydro-1-oxophthalazin-4-yl-acetate is obtained, m.p. 120-122С (recrystallized from a mixture of isopropanol and petrol (60-80) with a volume ratio of 1: 3), yield 4–3%. In Example 28, ethyl-2- (2-fluoro-4-bromobenzsh1) -6,7-methylenedia hydroxy-1,2-dihydro-1-oxophthalazin-4-yl acetate is obtained, m.p. 163-165 ° C (recrystallized from ethyl acetate), yield 50%. The starting materials are prepared in the following manner. Q) Etsh1-8-methyl-1,2-dihydro-1-oxoftalazin-4-yl-acetate (example 27). A solution of ethyl 4-methyl-3-oxo-D1a-phpanane acetate (3.5 g) in ethanol (100 ml) is stirred and heated under reflux during the process of adding dropwise hydrazine hydrate (15 ml of 1 M solution in ethanol). After the addition is complete, the mixture is stirred and heated under reflux for 3 hours and then left to stand at room temperature. The precipitated solid is collected and washed well with petrol (60-80) and recrystallized from an isopropanol mixture.
    3,4-Dichlrr 26
    7-fluorine
    29
    - -ten
    2-Fluoro-4- 60 bromine
    Diazomethane is obtained from 5c- (N-methyl-N-nitrozo) -terephthalamide using the method of Moore and Reed.
    The starting phthalazin-4-yl-carboxylic 7-Fluoro-1,2-dihydro-1-oxophthalacid is prepared as follows. Zin-5-yl-carboxylic acid (polus) 2- (3,4-Dichlorobenzene) -7-fluorinated as a solid,
    -1,2-dihydro-1-oxoftalazin-4-carbo-t.pp. 241-243C, 52% yield, median acid., VOM-developed procedure procedure
    i-PrOH
    160-162 and petrol (60-80) to form ethyl-8-methyl-1,2-dihydro-1-oxophthalazine-4-ip-acetate (1.0 g), tg. 197-199 ° C. 5) Ethyl-8-fluoro-1,2-dihydro-1-oxoftalazin-4-yl-acetate (Example 26). This ester is obtained as a solid, e.g. 207-210 ° C (recrystallized from ethyl acetate), yield 51%, from eth-1-4-fluoro-3-oxo-d1a-phthalane acetate and hydrazine hydrate using the procedure described in subsection Q (example 27). B) Ethyl-6,7-methylenedioxy-1,2-dihydro-I-oxoftalazin-4-yl-acetate (Example 28). This ester is obtained as a solid, m.p. 226-228C, yield 70%, from ethyl 5,6-methylenedioxy-3-oxo-a1a-phthalanacetate (A) and hydrazine hydrate. Phthaloacetate (A) is obtained as a solid, so pl. 189-191 with (recrystallized from ethanol), yield 64%, from 4,5-methylene-dioxyphthalic anhydride using the intermediates described in examples 23-25. Example 29-32. The process is carried out analogously to example 7. Esters having the formula (IV) are obtained from the corresponding starting materials (Table 4). Table 4
    et al.) convert the sodium salt thereof and react with iodomethane according to Example 8, to form a mixture of its methyl ester as a solid, m.p. 234-237C (recrystallized from a mixture of methanol and dimethylformamide with a volume ratio of 3: 1), yield 68%. This ester is then alkylated with 3,4-dichlorobenzene-5-chloride according to the procedure described in the eb example to form methyl l-2- (3,4-dichlorobenzyl) -7-fluoro-1,2-dihydro-1- oxophthalazin-4-yl-carboxylate, so pl. 147-149 ° C (recrystallized from a mixture of toluene and petrol (60-80) with a volume ratio of 1: 1), yield 68%. This ester is then hydrolyzed using a mixture of an aqueous solution of potassium carbonate and dioxane according to the procedure described in example 36, with the formation of 2- (3,4-dichlorobenzyl) -7-fluoro-1, 2-dihydro-1 -oxoftalazin-4-yl-carboxylic acid in the form of a solid substance, so pl. 222-224 C (recrystallized from isopropanol), yield 87%.
    S) 2- (3,4-Dichlorobenzyl) -6,7-dichloro-1, 2-dihydro-1-oxophapazin-4-yl-carbopic acid.
    This acid is obtained in a manner similar to that of p. A, and the corresponding intermediate substances, melting point, solvents, and the yield are as follows:
    6,7-dichloro-15 2-dihydro-1-oxoftalazin-4-carboxylic acid: mp. 294296 ° С (recrystallized: ayut from dimethylformamide), yield 42% 5 corresponding methyl ester: t, rh. 234-236 ° C (recrystallized from dimethylformamide), yield 51%;
    methyl 2- (3,4-dichlorobenzene 1) -6,7-dichloro-1, 2-dihydro-1-oxophthalazin-4-ylcarboxylate: mp. 155-156C (recrystallized from dimethylformamide), yield 85%;
    2- (3,4-dichlorobenzyl) -6,7-dichloro-1, 2-dihydro-1-oxophthalazin-4-yl-carboxylic acid: mp. 240-242 ° С
    (recrystallized from ethanol), yield 62%.
    ) 2- (3,4-Dd1 Chlorobenzyl) -6-: chloro-1, 2-dihydro-1-oxophthalazin-4-Sh1carboxylic acid.
    A solution of lithium butyl in hexane (165 ml of a 1.6 M solution) is slowly added to the stirred solution.
    2- (4-chlorophenyl) -4,4-dimethyl-2-oxazoline (50.5 g); in sodium salt, dried ether (600 ml) is contained at (-5) - (0) C and in an atmosphere of dry argon. After the addition is complete, stirring is continued at this temperature for 30 minutes, after which this solution is slowly added to a stirred solution of dry diethyl oxalate (326 ml) in ether (500 ml), which is at 0 ° C. When transferred, exposure to air and water is eliminated using a dry argon atmosphere. After the addition was completed, the reaction mixture was stirred and allowed to warm to room temperature for 1 hour. The ether mixture was then washed with water (2x150 ml), dried with MgSO4 and evaporated under reduced pressure (10 mm Hg) until All of the diethyl oxalate is removed. This residue is dissolved in dioxane (.500 ml and this solution is added to 5N hydrochloric acid (500 ml). This mixture is heated under reflux for 18 h, evaporated to half the volume, after the remaining solution is filtered. The filtrate is adjusted to pH 8 by adding hydrazine hydratemide, and the solution is heated for 30 minutes at 90 ° C and then acidified to pH 4 with concentrated hydrochloric acid. This mixture is cooled and the separated solid is collected by filtration, rinsed with water (2 x 500 ml) and dried in vacuum over phosphorus pentoxide to form 6-chloro-1,2-dihydro-1-oxophthalazin-4-yl-carboxylic acid (21.0 g).
    This acid is suspended in dimethylformamide (250 ml) and the mixture is treated with sodium carbonate (21.0 g and isomethane (40 ml). The combined mixture is stirred overnight and then diluted with water (250 ml). The precipitated solid is collected, washed with water (2x200 ml) and recrystallized from a mixture of isopropanol and dimethylformamide with a volume ratio of 2: 1, resulting in methyl 4-szhor-1,2-dihydro-oxoftal: azin-4-yl-carboxate 1 (17 , 0 g), mp 248-250 ° C.
    This ester is then reacted with 3,4-d11-chlorobenzyl chloride; gichn (1 volume, KPC described in p. A and e) Methyl-2- (3,4-dichlorobenzene 1) -6-chloro-1,2- dichloro-1-oxoftapazip-4-yl-carboxylate, mp 168-170 ° C. (recrystallized from toluene) in 45% yield, this ester is then hydrolyzed in item a, to form 2- (3.4- dichlorobenzyl) -6-chloro-1,2-dihydro-1-oxophthalazine-4-carboxylic acid, mp 222-223 ° C (recrystallized from ethanol) in 60% yield, d) 2- (2-Fluoro -4-bromobenzyl) -6-fluoro -1,2-dihydro-1-oxophthalazin-4-ylcarboxylic acid. This acid is obtained in a manner similar to & and related intermediates, melting points, solvents and yield values of the following methyl 6-fluoro-1,2-dihydro-1-oxofapazin-4-yl-carboxylate: mp 2121 223 C (recrystallized from methanol and dimethylformamide with a volume ratio of 2: 1), yield 15%; methyl 2- (2-fluoro-4-bromobenzsh1) -6-fluoro-1, 2-dihydro-1-oxophthalazin-4-yl-carboxylate: so pl. 131-134 ° C (recrystallized from methanol), yield 51%; 2- (2-fluoro-4-brombenzyl) -6-fluoro-1, 2-dihydro-1-oxophthalazin-4-yl-carboxylic acid: mp. 210-2 1 ° C (recrystallization from isopropanol), yield 70%. Example 33. The process is carried out analogously to example 16. Ethyl 2- (2-fluoro-4-bromobenzyl) -, 2-dihydro-1-thioxophthalazin-4-yl-acetate, m.p. 97-99 ° C (recrystallized from ethanol) in 22% yield by titration with ethyl 2- (2-fluoro-4-bromobenzyl) -, 2-dihydro-1-oxophthal azin-4-yl-acetate. Examples 34-37. A mixture of potassium carbonate (1.5 g), water (16 ml), dioxane (50 ml) and methyl-2- (2-fluoro-4Table 5-bromobenzyl) -8-fluoro-1, 2-dig1m-1) ovsoftapas1 n-4-yl-acetates (1.0 g) are heated under reflux for 24 hours, and then the evaporation is dissolved in water (100 mp) and the solution is washed with ether (2 x 100 ml). The aqueous phase is acidified to pH 2 by the addition of concentrated hydrochloric acid. The resulting solid is collected by filtration, rinsed with water and recrystallized from a mixture of toluene, isopropanol and petrol (60-80) with a volume ratio of 7: 1: 5, which gives 2- (2-fluoro-4-bromobenzyl) -8-fluoro - 1, 2-dihydro-1 -oxoftalazin-4-yl-acetic acid (Example 34) (0.5 g), m.p. 173-175 ° C. Using the same procedure and starting from the corresponding ethyl esters, the following acetic acid derivatives are obtained: Example 35. 2- (3,4-Dichlorobenzyl) -7-fluoro-1,2-dihydro-1-oxophthalazin-4-yl- acetic acid, T.Sh1. 20) -202 ° C (recrystallized from a mixture of ethyl acetate and petrol (60-80) with a volume ratio of 1: 2), yield 90%. Example 36. 2- (3,4-, Ll J-chlorobenzyl) -6, 7-dichloro-1, 2-d} G1-shchro-1-oxoftapazin-4-yl-acetic acid, m.p. 204-205 ° С (recrystallized from a mixture of methanol and dimethylformamide). Vkod 76%. Example 37. 2- (3,4-Dichlorobenzyl) -6-chloro-1,2-dihydro-1-oxophthalazi} -4-1x-acetic acid, mp. 208-209 ° C (recrystallized from isopropanol), yield 55%. Examples 38-50. The process is carried out analogously to example 4. By hydrolysis of the corresponding ethyl esters with potassium hydroxide, the following acetic acid derivatives are obtained having formula VI (Table 5). No 2-Fluoro-4,5- 71 dibromo - - 3,5-Dichloro-60 -4-bromo - - 2-Methoxy-55 -4-chloro 8-Fluoro 3,4-Dichl: op 68 6-Methyl 3 4-Dichloro 43 7-Methyl-2-Fluoro-48-Methyl bromo 3,4-Dichloro 44 47 6,7-Methn-2-Fluoro-4- 70 lendioxy bromo 6-Fluoro 8-Ethoxy 3,4-Dichloro 65 A mixture of 1: 2 6-methyl and 7-methyl derivatives. Exo-tautomer defined by
    In a similar way, by hydrolysis of the corresponding ester with an aqueous solution of sodium hydroxide in methanol, 2- (2-fluoro-4-bromobenzyl) -1,2-dihydro-1-thioxophthalazin-4-yl-acetic acid (Example 50) is obtained in a solid solid substances, so pl. 194-196 ° C (recrystallized from methanol) with 30% yield.
    Example 51. Ethyl-2- (3,4-dichlorobenzyl) -8-fluoro-1,2-dihydro-1-oxoftapazin-4-yl-acetate (1.8 g) is added to a solution of sodium (1.5 g ) in dry ethanol (150 ml). The resulting solution was heated under reflux for 3 hours and then evaporated. Water (100 ml) is added to the residue, the resulting solid is collected by filtration and dried to form these. Continuation of Table 5 1842191831.443182195203209187204-2- (3,4-dichlorobenzyl) -8-ethoxy-1,2-dihydro-1- oxoftapazin-4-yl-acetate (0.5 g).
    Example 52. A solution of sodium methylate (25 M.P 1.0 M solution in methanol) is added to a solution of 2- (2-fluoro-4-bromobenzyl) -1,2-dihydro-1-oxoftapazin-4-yl-acetic acid (9.87 g) in methanol (300 ml), after which the mixture is heated to its boiling point. Methanol is allowed to boil until the volume of the mixture is approximately 100 ml. After that, isopropanol (150 ml) is added to this mixture followed by (Petrol (60-80) follows, until the mixture becomes opaque. The mixture is then left to rise to room temperature. The resulting solid is separated by i-PrOH 186 i-PrOH 220 i-PrOH 184 EtOA / tolu145 ol (1: 2), 184 i-PrOH i-PrOH / pet197 rsl 60-80 (1: 2) i-PrOH / pet205 rsl 60-30 (1: 2 ) i-PrOH 210 i-PrOH 188 i-PrOH 206 NMR spectroscopy.
    filter grp.1;) iv, 131 P1a) with toluene (.2x400 ml), and then washed with ether (300 ml) to form 2- (2-fluoro-4-bromobenznl) -1,2-dihydro-1 - oxofalaznn-4-1SH-sodium adatate (6.5 g), m.p. 2-44-247 S.
    Example 53. 2- (Fluoro-4-bromo benzyl) -2- (2-fluorop-4-brombenziJI) - 1,2-dihydro-1-oxoftlazin-4-yl-acetate (0.9 g) is dissolved in ethanol
    (40 ml) containing potassium hydroxide (2.0 g), after which this mixture is heated under reflux for 90 minutes. The solvent was evaporated and water (100 ml) was added. The resulting bright solution is acidified with concentrated hydrochloric acid until pH 2 is reached. The precipitated solid is filtered off, washed well with water and dried in vacuo to give 2- (2-fluoro-4-bromobenzyl) -1,2-dihydro-1- oxophthalazin-4-yl-acetic acid (0.35 g) so pl. 181-183 ° C (after two recrystallization from methanol).
    The original substance is obtained as follows.
    1,2-Dihydro-1-ococaptazin-4-yl-ycyclic acid (2.0 g) is added to a solution of potassium carbonate (4.0 g) in dnmethylfloamide (50 ml). Bromide 2-fluoro-4-bromobenzyl (6.0 g) is added to this solution, after which the mixture is stirred for 15 hours at 60-70 ° C. The resulting solution was poured into water (400 ml). The precipitated solid is separated, rinsed well with water, dried under vacuum, and dissolved in et1-acetate. The resulting solution was filtered through a column of dry chromatographic silica gel (50 g), after which the fractions were collected. Additional etthta acetate is passed through the column, fractions containing the main non-polar component (determined by thin layer chromatography (SiO: toluene / EtOAc; volume ratio 3: 1) are combined) and extruded. The resulting solid is recrystallized twice from propane-2 -ola with the formation of 2-flu-4-bromobenzyl-2- (2-fluoro-4-bromobenzyl) -, 2-dihydro-1-oxoftalazin-4-Sh1-acetate (1.1 g), so pl. 125 -127 ° C
    (softens at 85 ° C). I
    Example 54. A solution of ethyl-2- (2,4-dichlorobenzyl) -1,2-dihydro-1-oxophthalazin-4-1 l-acetate (L) (1.0 g). In methanol (50 ml) containing 1M ipacTBOp sodium hydroxide (10 ml), stirred at room temperature (18–20 ° C) for 36 hours. This solution is then drunk into water (250 ml), and the resulting aqueous solution is extracted with ether (2 × 100 ml). The aqueous phase is acidified with concentrated hydrochloric acid (to pH 2). The isolated solid is collected, washed with water, dried under vacuum, and then recrystallized from methanol to form 2- (2,4-dichlorobenzyl) -1,2-dihydro-1-oxophthalazin-4-yl-acetic acid (0.8 g , 82%), mp. 192193 ° C.
    Example 55. The process is carried out analogously to example 54, but the starting product is a solution of 0.55 g of substance A in dioxane (50 ml) containing 2M hydrochloric acid solution (10 ml). The reaction mixture is heated at 45 ° C for 36 hours, and without extraction with ether, 2- (2,4-d1rsororbenzyl) -1,2-dihydrO-1-oxophthalazin-4-yl-acetic acid (0.39 g, 73%), mp. 192-194 ° C (recrystallized from methanol).
    The starting material (A) was obtained as a solid, so pl. , similar to example 1.
    The described procedure can be repeated for 18 h with the achievement of a 60% yield of 2- (2,4-dichlorobenzyl) -, 2-dihydro-I-oxophthalazin-4-yl-acetic acid.
    权利要求:
    Claims (1)
    [1]
    I
    Example 56. The procedure described in Example 54 is performed using a solution of butyl 2- (2-fluoro-4-bromobenzyl) -1,2-dihydro-1-oxophthalazin-4-yl-acetate, obtained as a solid. m.p. 87-88 ° C, as a result of applying a procedure similar to that described in example 1 (1.0 g) in ethanol (50 ml) containing 1M sodium hydroxide solution (10 ml); moreover, mixing is carried out at 40 ° C for 1 hour. Using the same developed procedure as in Example 54, 2- (2-fluoro-4-bromobenzyl) -1,2-dig1adro-I-oxophthalazin-4-yl is obtained β-acetic acid (0.6 g, 69%), so pl. 184-186 s (recrystallized from methanol). 2112 The ability to inhibit enzymatic aldose reductase can be demonstrated in the following standard laboratory test. Thus, diabetes is imparted to rats as a result of administration of streptozotocin, after which the test compound is administered to them for five days. The animals are then killed and removed from the i-ich lens of the eye and the sciatic nerves. After the standard processing procedure, residual levels of sorbitol are determined in each tissue, which is carried out by gas-liquid chromatography after it is converted to a polytrimethylsilyl derivative. The inhibition of aldose reductase in the living body is then assessed by comparing the residual levels of sorbitol in tissues taken from the diabetic group of rats to which the test compound was administered to the group of diabetic rats that were not administered the test compound and to the group of healthy rats that were not test compound was administered. Alternatively, a modified trial may be used whereby diabetic rats caused by administration of streptozotocin are given daily doses of the compound to be administered for two days. After 2 hours after the last dose, the animals were killed, their sciatic nerves were removed and their residual levels of sorbitol were determined in accordance with the method described by Bbmie. The active compounds used in any of these tests reduce the residual levels of sorbitol to levels similar to those in healthy ones; rats that did not receive this compound. However, in general, compounds having formula (I) provide significant inhibition of enzyme al-dose reductase with a dose administered through the oral cavity equal to 100 mg / kg or less. Thus, by illustrating it, it was established that 2- (2-fluoro-4-bromobenzyl) -1, 2-dihydro-1-oxophthalazin-4-yl-acetic acid allowed us to obtain a residual level of sorbitol in the sciatic nerve, equal to about 60 The% level detected in control diabetic rats of rats that did not administer this compound five days after ingestion of this compound through the oral cavity in an amount of 100 mg / kg. When receiving compounds having formula (I),. in an amount of 100 mg / kg, no obvious toxic or other undesirable effects were found during the tests described. The ability to inhibit enzymatic aldose reductase can also be demonstrated in laboratory conditions. For this, purified aldose reductase is obtained in a known manner from bovine eye lenses. The standard spectrophotometric methods then determine the percentage inhibition of this enzyme under laboratory conditions as a result of the reduction of aldose to polyhydric alcohols, in particular, the reduction of glucose to sorbitol under the influence of the test compound. In this test, compounds of formula (I) in which R represents a hydroxyl radical show significant inhibition of enzymatic aldose reductase at a concentration in the range of 10 -10 mol or less. Thus, 2- (2-fluoro-4-bromobenzyl) -, 2-dihydro-1-oxophthalazin-4-yl-acetic acid is characterized by an inhibition rate (KJ) of 2.0x10 mol. When the proposed compound is used to affect enzymatic aldose reductase in warm-blooded animals, it can be administered primarily through the oral cavity at a daily dose of 2-50 mg / kg, which is equivalent to a human at a total daily dose in the range of 20-750 mg per person given at necessary in separate doses. Data on aldose reductase inhibiting properties characteristic of phthalazin-4-sh1-acetic acids. The tests were carried out for 2-5 days. During this period, clear signs of toxicity were absent when using any of the tested compounds. The inhibitory activity of characteristic phthalazin-4-yl-acetic acids with respect to aldose reductase. Q) Male rats (110-130 g, the Alder and Park line have no specific pathogenicity) result in a diabetic condition in a known manner, administer streptozotocin, and hold for two weeks, after which they are checked for severe glucosuria. Thereafter, a test compound was orally administered daily to groups of six animals for 5 days. The animals are then killed and the sedan nerves are quickly removed from them. Tissue samples are weighed and carbohydrates are extracted by boiling in water, to which a known amount of o is added (methyl-B-mannoside as an internal standard. Protein compounds are removed, after which the protein-free solutions are lyo filmed. The remaining carbohydrate compound is then converted into the corresponding triethythylsilyl derivative and the residual concentration of sorbitol are determined by gas-liquid chromatography on a column with a carrier of 2.5% SE-52, (diatomite, C 80-100 mesh) prepared with acid and then silylated with dichloro etilsilana at 185 ° C. Inhibition apdozoreduktazy evaluated then compare va residual concentration of sorbitol in the tissues of the group of diabetic rats with the administration of the compounds and tissues group of diabetic rats administered only invert pharmaceutical carrier. This test is known as the P-day old test.
    4-Br
    em 4-13-Ct-4-Br OH O
    2-F-4-Br OH S
    em
    Table 6
    36 66 32 80 33 31
    50
    OH О 100 20 50 20 OH О
    ten
    66,100
    36
    20 5) Groups of 6 rats in which the diabetic condition is caused by the streptozotoic one, twice orally administered doses of the compound, with an interval between doses of 17 hours. 2-4 hours after the last dose, animals are slaughtered, sciatic nerves are removed and residual sorbitol according to the method described in p. This test is known as the Two-Day Test. Test compounds are considered active in tests a or 5 if they reduce the concentration of sorbitol in the sciatic nerve by at least 25% compared with this concentration in diabetic rats that were administered only an inert pharmaceutical carrier, with an oral dose of 100 mg / kg or less. Results Using methods a or S, the following effect was found on the concentration of sorbitol in the sciatic nerve using representatives of phthalazin-4-yl-acetic acid derivatives having the following formula. The results are shown in Table. 6
    25
    26
    1272984 Continuation of table 6
     The percentage decrease in the concentration of sorbitol in the sciatic nerve compared with the concentration in the control rats diabetics who were not administered drugs (, 1, usually 0.01); A mixture of 1: 1 6-methyl and 7-methyl derivatives. For comparison, the structurally similar compound 1-benzyl-1, 2-dihydro-1-oxophthalazin-4-yl-acetic acid causes an increase of 2% (with an oral dose of 200 mg / kg) and an increase of 12% (with oral dose of 100 mg / kg) the concentration of sorbitol in the sciatic nerve compared with the concentration in control - animals.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1272984A3|1986-11-23|Method of producing phthalazin-4-yl-acetic acid derivatives or salts thereof
    EP0269378A1|1988-06-01|Quinazolinone derivative and processes for preparing the same
    JP2001505198A|2001-04-17|Substituted dihydrobenzofurans as PDE inhibitors
    FR2731708A1|1996-09-20|PIPERIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR THERAPEUTIC APPLICATION
    JP2961013B2|1999-10-12|[| methyl] -2a, 3,4,5-tetrahydro-1 | -acenaphthylene-1-ones and related compounds
    JP3107784B2|2000-11-13|Acid addition salts of optically active piperidine derivatives and their preparation
    US4168380A|1979-09-18|7-Methoxy-5-oxo-5H-thiazolo[2,3-b]quinazoline-2-carboxylic acid
    US5185360A|1993-02-09|Dihydroindenoindole compounds and methods for using the same
    US4209527A|1980-06-24|Benzimidazolone derivatives
    EP0014079B1|1981-11-18|Spiro-quinolylhydantoins, process for their preparation and pharmaceutical compositions thereof
    WO1993013092A1|1993-07-08|Imidazolidinedione derivatives
    IE57520B1|1993-05-19|Imidazolidinedione derivatives
    JP3042902B2|2000-05-22|Hexahydropyrrolo [2,3-b] indolecarbamate, -urea, -amide and related compounds
    EP0471296B1|1995-11-08|1-|-1H-indoles, indolines and related analogs
    EP0017477A1|1980-10-15|Spiro-quinolone hydantoins, pharmaceutical compositions containing them, and processes for their preparation
    CA1217185A|1987-01-27|Bronchodilatory azepino [1,2-a] pyrimideinederivatives and acid addition salts thereof andpharmaceutical compositions containing same
    JPH0751566B2|1995-06-05|2-Piperazinopyrimidine derivative
    JP3059572B2|2000-07-04|Pyrrolo [3,2-e] pyrazolo [1,5-a] pyrimidine derivatives and therapeutic agents for hypertension containing the same as an active ingredient
    KR860001870B1|1986-10-24|Process for preparing imidazolidinedione derivatives
    US4382088A|1983-05-03|4,7-Dihydro-4,7-dioxi-1H-cyclohepta[b]pyridine derivatives
    JPH06199851A|1994-07-19|Quinoline-3-acetic acid derivative, its production and use
    KR820001929B1|1982-10-20|Process for preparing phthalazin-4-ylacetic acid derivatives
    JPH07316135A|1995-12-05|Acrudone derivative and production thereof
    IL45347A|1977-01-31|7h-indolizino|isoquinoline derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
    KR20020094065A|2002-12-18|Novel Quinoline derivatives, the process for the preparation thereof and pharmaceutical compositions containing them
    同族专利:
    公开号 | 公开日
    DK541878A|1979-06-30|
    US4393062A|1983-07-12|
    AU4204078A|1979-07-05|
    IN150196B|1982-08-14|
    YU42054B|1988-04-30|
    JPS5495582A|1979-07-28|
    IE782337L|1979-06-29|
    AT365581B|1982-01-25|
    SU1072803A3|1984-02-07|
    HU182585B|1984-02-28|
    ES476496A1|1979-04-16|
    FI64357B|1983-07-29|
    YU42807B|1988-12-31|
    DD141021A5|1980-04-09|
    NO154346B|1986-05-26|
    FI783844A|1979-06-30|
    GR65303B|1980-08-01|
    CS241015B2|1986-03-13|
    AU516264B2|1981-05-28|
    JPS6326110B2|1988-05-27|
    YU232182A|1983-01-21|
    YU312778A|1983-01-21|
    IT1110885B|1986-01-06|
    BG34336A3|1983-08-15|
    HK22484A|1984-03-23|
    YU232082A|1983-01-21|
    DK151253B|1987-11-16|
    MY8500359A|1985-12-31|
    IT7852480D0|1978-12-28|
    FI64357C|1983-11-10|
    IE47592B1|1984-05-02|
    DK151253C|1988-05-16|
    YU41607B|1987-12-31|
    JPS63119469A|1988-05-24|
    JPH0262532B2|1990-12-26|
    SG68683G|1984-08-03|
    NZ189034A|1981-11-19|
    ZW24978A1|1980-10-22|
    DE2861170D1|1981-12-24|
    PT68956A|1979-01-01|
    CY1219A|1984-04-06|
    US4251528A|1981-02-17|
    EP0002895B1|1981-10-14|
    NO784397L|1979-07-02|
    EP0002895A1|1979-07-11|
    IL56099D0|1979-01-31|
    CA1107732A|1981-08-25|
    PH15435A|1983-01-18|
    PL118443B1|1981-10-31|
    NO154346C|1986-09-03|
    SU1087075A3|1984-04-15|
    ATA937678A|1981-06-15|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3833579A|1935-11-11|1974-09-03|Inoue Michiro|4-carbamoyl phthalazones|
    JPS5116430B2|1971-08-05|1976-05-24|
    GB1398549A|1972-11-06|1975-06-25|Boots Co Ltd|Phthalazine derivatives and their use in pharmaceutical compo sitions|
    AR205004A1|1973-10-30|1976-03-31|Ishikawa M|PROCEDURE TO PREPARE 6,8-DIALKYL-7-ALCOXY-CARBONYL-4-HYDROXIMETHYL-1-PHTHALAZONE AND 7,8-LACTONE DERIVATIVES|
    DE2451117A1|1973-10-31|1975-05-22|Boots Co Ltd|THERAPEUTICALLY EFFECTIVE COMPOUNDS|
    GB1502312A|1975-03-20|1978-03-01|Ici Ltd|Quinolone derivatives|
    IE43079B1|1975-03-20|1980-12-17|Ici Ltd|Quinolone derivatives|
    JPS5214788A|1975-07-21|1977-02-03|Fuji Photo Film Co Ltd|Process for preparing phthalazinone and its derivatives|
    NL7702763A|1976-03-18|1977-09-20|Takio Shimamoto En Masayuki Is|PROCESS FOR THE PREPARATION OF THROMBOXAN ANTAGONISTS AND OF PREPARATIONS CONTAINING THESE SUBSTANCES.|
    IE47592B1|1977-12-29|1984-05-02|Ici Ltd|Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture|
    US4293553A|1978-08-11|1981-10-06|Masayuki Ishikawa|1-Phthalazone derivatives, and use thereof|IE47592B1|1977-12-29|1984-05-02|Ici Ltd|Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture|
    CA1143733A|1979-07-31|1983-03-29|Masao Yoshida|Producing 7-alkoxycarbonyl-6,8-dimethyl-4-hydroxymethyl-1-phthalazone and intermediates|
    US4762839A|1985-06-06|1988-08-09|Tanabe Seiyaku Co., Ltd.|Quinazolinone copmpounds useful for the prophyloxis and treatment of diabetic complications|
    IL80475A|1985-11-07|1993-01-31|Pfizer|Heterocyclic-substituted 4-oxo -3h- phthalazinyl-acetic acid derivatives and pharmaceutical compositions containing them|
    JPH0476994B2|1986-11-21|1992-12-07|Tanabe Seiyaku Co|
    US5011840A|1986-11-24|1991-04-30|Pfizer Inc.|Imidazolidinedione derivatives in diabetes treatment|
    GB8704569D0|1987-02-26|1987-04-01|Ici America Inc|Therapeutic agent|
    JPH0676391B2|1987-06-09|1994-09-28|フアイザー・インコーポレイテツド|Process for producing oxophthalazinyl acetic acid having heterocyclic side chain such as benzothiazole|
    US4868301A|1987-06-09|1989-09-19|Pfizer Inc.|Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains|
    EP0315249A1|1987-11-02|1989-05-10|Merck & Co. Inc.|Phthalazineacetic acid composition and tablet|
    DK607188A|1987-11-02|1989-06-22|Merck & Co Inc|TABLE CONTAINING A PHTHALAZINE ACETIC ACID COMPOUND|
    US4880928A|1987-12-21|1989-11-14|Merck & Co., Inc.|Process for the preparation of 3-methyl)-3,4-dihydro-4-oxo-1-phthalazine-acetic acid|
    US4904782A|1988-02-29|1990-02-27|Pfizer Inc.|Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate|
    US4940791A|1988-02-29|1990-07-10|Pfizer Inc.|Process for the production of phthalazineacetic acid ester derivatives and a novel hydrazine containing intermediate|
    US4996204A|1989-05-11|1991-02-26|Pfizer Inc.|Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors|
    US4954629A|1989-05-11|1990-09-04|Pfizer Inc.|Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof|
    EP0397930A1|1989-05-18|1990-11-22|Merck & Co. Inc.|Process for the preparation of 3-[ methyl]-3,4-dihydro-4-oxo-1-phthalazineacetic acid|
    FR2647676A1|1989-06-05|1990-12-07|Union Pharma Scient Appl|New pyridazinone derivatives, processes for preparing them and medicaments containing them which are useful, in particular, as aldose reductase inhibitors|
    US5304557A|1989-12-15|1994-04-19|Pfizer Inc.|Substituted oxoophthalazinyl acetic acids and analogs thereof|
    US5037831A|1990-05-21|1991-08-06|American Home Products Corporation|Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors|
    FR2682108B1|1991-10-07|1994-01-07|Lipha|3,4-DIHYDRO-4-OXO-3-1-PHTHALAZINEACETICS AND DERIVATIVES, THEIR PREPARATIONS AND MEDICINES CONTAINING THEM.|
    JP2789134B2|1992-09-28|1998-08-20|ファイザー・インク．|Substituted pyrimidines control diabetic complications|
    CA2147504A1|1992-11-02|1994-05-11|Prasun K. Chakravarty|Substituted phthalazinones as neurotensin antagonists|
    CH683965A5|1993-02-19|1994-06-30|Limad Marketing Exp & Imp|Ftalidrazidici compounds of the class as an active substance in anti-inflammatory agents and anti-toxic.|
    WO1995003053A1|1993-07-26|1995-02-02|Fujisawa Pharmaceutical Co., Ltd.|Oxophthalazines for treating cachexia|
    US6696407B1|1997-03-21|2004-02-24|The Regents Of The University Of California|Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF|
    WO1998042324A2|1997-03-21|1998-10-01|The Regents Of The University Of California|Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors|
    EP0973534B1|1997-04-15|2006-11-02|Csir|Plant extracts having appetite suppressant activity|
    DE69918278T2|1998-03-31|2005-07-14|The Institutes for Pharmaceutical Discovery, Inc., Branford|SUBSTITUTED INDOLALCANIC ACID|
    TNSN99224A1|1998-12-01|2005-11-10|Inst For Pharm Discovery Inc|METHODS OF REDUCING GLUCOSE AND TRIGLYCERIDE LEVELS IN SERUM AND FOR ANTIGENESIS SUPPRESSION USING INDOLEALKANOIC ACIDS|
    GB2355657B|1999-10-27|2004-07-28|Phytopharm Plc|Inhibitors Of Gastric Acid Secretion|
    DE19963607B4|1999-12-23|2005-12-15|Schering Ag|Process for the preparation of 4-halo-1-phthalazinones|
    GB2363985B|2000-06-30|2004-09-29|Phytopharm Plc|Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use|
    SK6092003A3|2000-11-30|2004-07-07|Pfizer Prod Inc|Combination of GABA agonists and aldosereductase inhibitors|
    ES2240657T3|2001-02-28|2005-10-16|Pfizer Products Inc.|SULFONILPIRIDAZINONA COMPOUNDS USEFUL AS INHIBITORS OF ALDOSA REDUCTASA.|
    US7572910B2|2003-02-20|2009-08-11|Pfizer, Inc.|Pyridazinone aldose reductase inhibitors|
    DE60202452C5|2001-03-30|2006-11-23|Pfizer Products Inc., Groton|PYRIDAZINONAL DOSE REDUCTASE INHIBITORS|
    IL157935D0|2001-04-30|2004-03-28|Pfizer Prod Inc|Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors|
    AU761191B2|2001-05-24|2003-05-29|Pfizer Products Inc.|Therapies for tissue damage resulting from ischemia|
    US20050209237A1|2002-04-30|2005-09-22|Brazzell Romulus K|Method for decreasing capillary permeability in the retina|
    CN1684685A|2002-07-26|2005-10-19|药物研发有限责任公司|Substituted indolealkanoic acids derivative and formulations containing same for use in treatment of diabetic complications|
    US20110092566A1|2004-11-19|2011-04-21|Srivastava Satish K|Treatment of cancer with aldose reductase inhibitors|
    JP4838582B2|2004-12-27|2011-12-14|岐阜プラスチック工業株式会社|Body for cart|
    AT518544T|2007-03-12|2011-08-15|Zadec Aps|REDBUSCH EXTRACT AGAINST DIABETES|
    EP2139330B1|2007-03-23|2014-09-24|The Board of Regents of The University of Texas System|Methods involving aldose reductase inhibitors|
    US20090270490A1|2008-04-24|2009-10-29|The Board Of Regents Of The University Of Texas System|Methods involving aldose reductase inhibition|
    CA2822672C|2010-12-23|2018-06-05|The Board Of Regents Of The University Of Texas System|Methods for treating copd|
    CA2895162C|2012-12-14|2021-03-09|D. Lynn Kirkpatrick|Methods and compositions for inhibiting cnksr1|
    CA2983260A1|2015-04-20|2016-10-27|Phusis Therapeutics, Inc.|Compounds, compositions and methods for inhibiting cnksr1|
    US20220001582A1|2018-10-04|2022-01-06|Nitto Denko Corporation|Heat-resistant release sheet and thermocompression bonding method|
    JP6751974B1|2019-10-16|2020-09-09|株式会社コバヤシ|Release film and method for manufacturing release film|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB5414277|1977-12-29|
    [返回顶部]